Hematologic adverse effects of clopidogrel

American Journal of Therapeutics

Volumn 14, Issue 1, 2007, Pages 106-112

  Balamuthusamy, Saravanan ^a,b   Arora, Rohit ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b The Chicago Medical College   (United States)

Author keywords

Acquired hemophilia; Autoimmune thrombocytopenia; Clopidogrel; Neutropenia; Plavix; Purpura; Thrombocytopenia

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; ACETYLSALICYLIC ACID; AZATHIOPRINE; CLOPIDOGREL; DRUG METABOLITE; IMMUNOGLOBULIN; MEPREDNISONE; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TICLOPIDINE;

AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW TOXICITY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; HEART INFARCTION; HEART SURGERY; HEMATOLOGIC DISEASE; HEMOLYTIC UREMIC SYNDROME; HEMOPHILIA; HUMAN; LIVER METABOLISM; MEDLINE; META ANALYSIS; NEUTROPENIA; PERIPHERAL VASCULAR DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

CLINICAL TRIALS; HEMATOLOGIC DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TICLOPIDINE;

EID: 33847151775     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000212708.81034.22     Document Type: Review

References (48)

1. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Am Soc Pharmacol Exp Ther. 2002;11:1288-1295.
2. Thebault JJ, Kieffer G, Lowe GD, et al. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Seminol Thromb Hemostasis. 1999;25:9-14.
3. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339.
4. Mehta SR, Yusuf S, for CURE Study Investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21:2033-2041.
5. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel with clopidogrel alone after recent ischeamic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
6. Steinbul S, Berber P, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
7. Sabastine MS, Cannon CP, Gibson CM, et al. CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
8. Micheal EB, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation. 2000;102:624.
9. Andres E, Perrin AE, Alt M, et al. Febrile pancytopenia associated with Clopidogrel. Arch Inter Med. 2001;161:125.
10. Akcay A, Kanbay M, Agca E, et al. Neutropenia due to clopidogrel in a patient with end-stage renal disease. Ann Pharmacother. 2004;38:1538-1539.
11. Casella G, Ottani F, Pavesi PC, et al. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated metaanalysis. Italian Heart J. 2003;4:677-684.
12. Akcay A, Kanbay M, and Agca E. Ann Pharmacother. 37:216-219. DOI 10.1345/aph.1C233.
13. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmö Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105:2287-2293.
14. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor eight. Thromb Hemostasis. 1981;45:200-203.
15. Haj M, Dasani H, Kundu S, et al. Acquired haemophilia A may be associated with clopidogrel. Br Med J. 2004;329:323.
16. Morrison AE, Ludlum CA. Acquired hemophilia and its management. Br J Haematol. 1995;89:213-216.
17. Haj M, Dasani H, Kundu S, et al. Acquired hemophilia may be associatedwith clopidogrel. Br Med J. 2004;329:323.
18. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
19. Elmi F, Peacock T, Schiavone J. Isolated profound thrombocytopenia associated with clopidogrel. J Invasive Cardiol. 2000;12:532-535.
20. Chen-Hung Su, Chin-Feng Tsai, Kwo-Chang Ueng, et al. Clopidogrel associated severe Isolated Thrombocytopenia: A case report. Acta Cardiol Sin. 2004;20:182-186.
21. Best PJ, Mathew V, Markovic SN. Catheter Cardiovascular Intervention. 2004;62:339-340.
22. Bennet CI, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.
23. Amorosi E, Ultmann J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45:139-159.
24. Navneet SM, Alan EL. Clopidogrel and thrombotic thrombocytopenic purpura: no clear cause for causality. Cleveland Clin J Med. 2003;70:466-470.
25. Gordon LI, Kwaan HC. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997;34:140-147.
26. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
27. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
28. Moake JL. Moschcowitz. multimers and metalloprotease. N Engl J Med. 1998;339:1629-1631.
29. Connors JM, Gopfert C, Robson S, et al. Clopidogrel associated TTP. Transfusion. 1999;39:56S-56S. Abstract.
30. Carwile JM, Laber DA, Soltero ER, et al. Thrombotic thrombocytopenic purpura occurring after exposure to clopidogrel. Blood. 1999;94:78b-78b. Abstract.
31. Bennet CL, Weinberg PD, Rozenberg-Ben-Dor K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Internal Med. 1998;128:541-544.
32. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA. 1998;281:806-810.
33. Majhail NS, Lichtin AE. Plasmapheresis improves survival in drug-induced thrombotic thrombocytopenic purpura: systematic review of published case reports. Blood. 2001;98:60b.
34. Anaadriana Z, Nicholas B, Dilip K, et al. Clopidogrelassociated TTP. Stroke. 2004;35:533.
35. Martin DL, MacDonald KL, White KE. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med. 1990;323:1161-1167.
36. Medina PJ, Sipols JM, George JN. Drug associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001;8:286-293.
37. Andre AK. Aphaeresis for renal disease. Ther Aphaeresis Dialysis. 2001;5.2:134-141.
38. Evens AM, Kwaan HC, Kaufman DB. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation. 2002;74:885-887.
39. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004;110:1168-1176.
40. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004;128:425-431.
41. Chu MW, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004;78:1536-1541.
42. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231-237.
43. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35:1288-1294.
44. Wilson S, Fasseas P, Orford J, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol. 2003;42:234-240.
45. Morice M, Serruys P, Sousa J, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
46. Schofer J, Schluter M, Gershlick A, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099.
47. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
48. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.